Directly Observed Antiretroviral Therapy Among Active Drug Users
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00367172|
Recruitment Status : Completed
First Posted : August 22, 2006
Last Update Posted : August 6, 2009
|Condition or disease||Intervention/treatment||Phase|
|HIV/AIDS Substance Abuse||Behavioral: Directly Administered Antiretroviral Therapy||Not Applicable|
Highly active antiretroviral therapy (HAART) has dramatically reduced morbidity and mortality from HIV disease, but these benefits have not been conferred equally among all patient populations. Injection drug users (IDUs) have shown particularly less favorable outcomes, with HIV progression remaining at high levels, and IDU remains a significant risk behavior for the spread of HIV worldwide, with explosive epidemics in Eastern Europe, Russia, and Southeast Asia. It is therefore essential to develop and test strategies of HIV treatment that optimize outcomes for this population, in order to reduce morbidity and mortality and to curb secondary transmission.
Directly observed therapy (DOT) for tuberculosis has resulted in impressive improvements in adherence and clinical response and marked reductions in the development of resistance. The time-limited treatment of tuberculosis, the inherently different transmission patterns of tuberculosis and HIV, and the complexity of antiretroviral therapy have raised concerns about translating the DOT model to HIV. Successful, but non-comparative demonstration programs of directly administered antiretroviral therapy (DAART) have been implemented in methadone maintenance programs, community-based settings, skilled nursing facilities, and in prisons. None of these, however, have targeted active drug users or used a prospective, randomized controlled trial (RCT) design to rigorously determine the efficacy of DAART as an intervention to improve HIV outcomes among active drug users. One RCT of DAART recently failed to demonstrate an impact on virological outcomes among low-income HIV+ patients, but these results are unlikely to be applicable to IDUs or other populations with demonstrated problematic adherence.
We therefore conducted the first randomized controlled trial to address this question, consisting of six months of DAART versus self-administered therapy (SAT) among active drug users in a community setting. The objective was to determine the potential efficacy of a six-month DAART program on HIV infection, using surrogate markers of HIV- RNA levels and CD4+ T lymphocyte counts.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||125 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Directly Observed Antiretroviral Therapy Among Active Drug Users|
|Study Start Date :||June 2001|
|Actual Primary Completion Date :||June 2006|
|Actual Study Completion Date :||December 2006|
- Virological Success, defined as greater than 1 Log HIV-1 Copies/mL reduction or Viral Load Less than 400 copies/mL at the end of six months on the intervention.
- Mean change in HIV-1 viral load from baseline to six months at the end of the intervention.
- Virological Success at six months following the termination of the intervention.
- 3-Day Recall measures of adherence at the end of six months on the intervention.
- Mean change in HIV-1 viral load from baseline six months following the termination of the intervention.
- Mean change in CD4+ T cells from baseline to the end of six months on the intervention.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00367172
|United States, Connecticut|
|Yale University School of Medicine|
|New Haven, Connecticut, United States, 06510|
|Principal Investigator:||Frederick L Altice, M.D.||Yale AIDS Program|
|Principal Investigator:||Gerald H Friedland||Yale AIDS Program|